Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Down 0.6% – Should You Sell?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) was down 0.6% on Monday . The company traded as low as $1.7150 and last traded at $1.74. 144,711 shares traded hands during trading, a decline of 70% from the average session volume of 487,326 shares. The stock had previously closed at $1.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Acrivon Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Acrivon Therapeutics Trading Down 0.6%

The stock has a market capitalization of $74.47 million, a P/E ratio of -0.87 and a beta of 1.82. The stock’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.74.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). On average, sell-side analysts expect that Acrivon Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of hedge funds have recently bought and sold shares of ACRV. Focus Partners Wealth bought a new stake in Acrivon Therapeutics in the third quarter valued at about $36,000. Schonfeld Strategic Advisors LLC acquired a new stake in Acrivon Therapeutics during the fourth quarter valued at approximately $40,000. Vermillion & White Wealth Management Group LLC bought a new position in Acrivon Therapeutics during the 4th quarter worth approximately $44,000. Quadrature Capital Ltd bought a new position in Acrivon Therapeutics during the 4th quarter worth approximately $50,000. Finally, Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics in the 1st quarter worth approximately $72,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.